Table 2.
Clinical characteristics at baseline.
| Denosumab group |
Teriparatide group |
P-value | |
|---|---|---|---|
| Characteristics | n = 20 | n = 21 | |
| Age, years | 66.7 ± 10.7 | 61.1 ± 11.7 | 0.07 |
| Female, % | 95 | 100 | 0.49 |
| BMI, kg/m2 | 21.3 ± 3.3 | 19.4 ± 2.9 | 0.35 |
| Duration of prednisolone treatment, months | 177.7 ± 99.6 | 185.5 ± 116.1 | 0.96 |
| Dose of prednisolone at entry, mg | 6.3 ± 4.7 | 5.7 ± 3.5 | 0.78 |
| Duration of bisphosphonate treatment, months | 138.7 ± 88.7 | 134.7 ± 75.7 | 0.97 |
| BMD, g/cm2 | |||
| Lumbar spine | 0.74 ± 0.11 | 0.73 ± 0.11 | 0.65 |
| T score | −2.59 ± 1.02 | −2.77 ± 1.08 | 0.51 |
| Femoral neck | 0.50 ± 0.08 | 0.50 ± 0.06 | 0.57 |
| T score | −2.70 ± 0.63 | −2.61 ± 0.52 | 0.49 |
| Total hip | 0.63 ± 0.09 | 0.64 ± 0.09 | 0.74 |
| T score | −2.13 ± 0.69 | −2.02 ± 0.87 | 0.70 |
| Bone turnover markers | |||
| Serum TRACP-5b, mU/dL | 314.7 ± 134.4 | 269.5 ± 138.4 | 0.27 |
| Serum P1NP, μg/L | 30.5 ± 20.6 | 26.4 ± 19.7 | 0.26 |
Data are mean ± SD. BMI, body mass index; BMD, bone mineral density; TRACP-5b, tartrate-resistant acid phosphatase 5b; P1NP, procollagen type 1 N-terminal propeptide.